ZEISS Ventures — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
.png)
HyperSpectral develops a spectral sensing and AI layer for Physical AI that interprets matter through spectral data, molecular identification, and AI architecture.
AI & Machine LearningDeep TechDefense TechHardwareAlexandria, US
Matthew Theurer(Executive Officer, Director)Lauren Stack(Executive Officer, Director)inVincent Lubsey(Executive Officer)
BoardJuan Lopez(Director)inWilliam Porteous(Director)in
Co-investorsKibo VenturesAngelini VenturesGlade Brook Capital PartnersHeal CapitalLifeX VenturesRRE Ventures
Hypervision Surgical develops an intraoperative hyperspectral imaging system that uses AI to provide real-time, contrast-free tissue characterisation during surgery.
AI & Machine LearningHealthtechMedical Devices
Co-investorsHeal CapitalHeran PartnersLifeX VenturesMeridian Health VenturesSonorcapAngelini Ventures+1 more
Maculaser develops a temperature-controlled retinal laser therapy to treat age-related macular degeneration, diabetic macular edema, and other retinal disorders by activating natural healing responses in eye cells.
BiotechDeep TechHealthtechMedical DevicesHelsinki, FI
Jani Tirronen(CEO)inTeemu Turunen(Chief Scientific Officer, PhD)inOssi Kaikkonen(Head of Product)inJaakko Nieminen(CTO, PhD)in
Co-investorsInnovestor Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.